Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 10/20 | 0.70 |
| ▸ | HTR3A | P46098 | 7/20 | 0.59 |
| ▸ | HTR3E | A5X5Y0 | 5/20 | 0.59 |
| ▸ | HTR3B | O95264 | 5/20 | 0.59 |
| ▸ | HTR3D | Q70Z44 | 5/20 | 0.59 |
| ▸ | HTR3C | Q8WXA8 | 5/20 | 0.59 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.59 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL261183 | 1.00 | CHRNA7 (0.70) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL260541 | 1.00 | CHRNA7 (0.70) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL6389991 | 0.94 | CHRNA7 (0.62) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| Fumaric Acid SCHEMBL6681390 | 0.94 | CHRNA7 (0.62) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| Fumaric Acid SCHEMBL6681396 | 0.94 | CHRNA7 (0.62) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL261949 | 0.91 | CHRNA7 (0.64) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL4914104 | 0.91 | CHRNA7 (0.64) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL261080 | 0.91 | CHRNA7 (0.64) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| SCHEMBL260378 | 0.91 | CHRNA7 (0.64) | CHRNA7HTR3AHTR3EHTR3BHTR3D | |
| Fumaric Acid SCHEMBL6387395 | 0.88 | CHRNA7 (0.55) | CHRNA7HTR3AHTR3EHTR3BHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060019984-A1 | Treatment of diseases with alpha-7nACh receptor full agonists | PFIZER INC | 2006-01-26 | — | — | US | claimed |
| US-20050245504-A1 | Treatment of diseases with combinations of alpha 7 Nicotinic Acetylcholine Receptor agonists and other compounds | CORBETT JEFFREY W | 2005-11-03 | — | — | US | claimed |
| EP-1587511-A2 | TREATMENT OF DISEASES WITH ALPHA-7 NACH RECEPTOR FULL AGONISTS | Pharmacia & Upjohn Company LLC (US) | 2005-10-26 | — | — | EP | claimed |
| EP-1572205-A2 | TREATMENT OF DISEASES WITH COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS AND OTHER COMPOUNDS | Pharmacia & Upjohn Company LLC (US) | 2005-09-14 | — | — | EP | claimed |
| EP-1572300-A1 | COMBINATION FOR THE TREATMENT OF ADHD | Pharmacia & Upjohn Company LLC (US) | 2005-09-14 | — | — | EP | claimed |
| US-20050107425-A1 | Treatment of attention defecit hyperactivity disorder | PFIZER INC | 2005-05-19 | — | — | US | claimed |
| US-6828330-B2 | Central nervous system disorders; schizophrenia; psychological disorders | PHARMACIA & UPJOHN COMPANY | 2004-12-07 | — | — | US | claimed |
| US-20040224977-A1 | Quinuclidine-substituted hetero-bicyclic aromatic compounds for the treatment of disease | WALKER DANIEL PATRICK (US) | 2004-11-11 | — | — | US | claimed |
| WO-2004064836-A2 | TREATMENT OF DISEASES WITH ALPHA-7 NACH RECEPTOR FULL AGONISTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-08-05 | — | — | WO | claimed |
| WO-2004052461-A1 | COMBINATION FOR THE TREATMENT OF ADHD | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-06-24 | — | — | WO | claimed |
| WO-2004052348-A2 | TREATMENT OF DISEASES WITH COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS AND OTHER COMPOUNDS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-06-24 | — | — | WO | claimed |
| EP-1404674-A2 | QUINUCLIDINE-SUBSTITUTED HETEROAROMATIC COMPOUNDS AS LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS | PHARMACIA & UPJOHN COMPANY (US) | 2004-04-07 | — | — | EP | claimed |
| US-20030073707-A1 | Quinuclidine-substituted hetero-bicyclic aromatic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-04-17 | — | — | US | claimed |
| WO-2002100858-A2 | QUINUCLIDINE-SUBSTITUTED HETEROAROMATIC COMPOUNDS AS LIGANDS AT NICOTINIC ACETYLCHOLINE RECEPTORS | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-19 | — | — | WO | claimed |
| EP-1543000-B1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | MEMORY PHARM CORP (US) | 2013-03-06 | — | — | EP | disclosed |
| US-8252811-B2 | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2012-08-28 | — | — | US | disclosed |
| US-20120101094-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE (US) | 2012-04-26 | — | — | US | disclosed |
| WO-2004039366-A1 | NICOTINIC ACETYLCHOLINE AGONISTS IN THE TREATMENT OF GLAUCOMA AND RETINAL NEUROPATHY | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-05-13 | — | — | WO | disclosed |
| WO-2004029050-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-04-08 | — | — | WO | disclosed |
| US-20030073707-A1 | Quinuclidine-substituted hetero-bicyclic aromatic compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245504-A1 | Treatment of diseases with combinations of alpha 7 Nicotinic Acetylcholine Receptor agonists and other compounds | CHRNA7, CHRNG, CHRNE | CHRNA7 1/4885HTR3A 497/4885HTR3E 673/4885 |
| US-20120101094-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | CHRNA7, CHRNA5, CHRNA3 | CHRNA7 1/4885HTR3A 152/4885HTR3E 224/4885 |
| US-20030073707-A1 | Quinuclidine-substituted hetero-bicyclic aromatic compounds for the treatment of disease | NAT1, UGT1A1, SLC10A1 | CHRNA7 672/4885HTR3A 1351/4885HTR3E 1837/4885 |
| US-20060019984-A1 | Treatment of diseases with alpha-7nACh receptor full agonists | CHRNA7, CHRNA1, CHRNG | CHRNA7 1/4885HTR3A 426/4885HTR3E 837/4885 |
| US-20040224977-A1 | Quinuclidine-substituted hetero-bicyclic aromatic compounds for the treatment of disease | NAT1, UGT1A1, SLC10A1 | CHRNA7 672/4885HTR3A 1351/4885HTR3E 1837/4885 |
| US-20050107425-A1 | Treatment of attention defecit hyperactivity disorder | CHRNA7, CHRNA10, SLC18A3 | CHRNA7 1/4885HTR3A 32/4885HTR3E 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.